Comparing two antipsychotic medicines for psychosis in Lewy body disease
Compares pimavanserin and quetiapine for hallucinations and delusions in Parkinson's or Lewy body dementia.
Key facts
- Who runs it
- The University of Texas Health Science Center at San Antonio
- Where
- San Antonio, United StatesSee the 2 sites
- Trial code
- Registry title
- Comparing Antipsychotic Medications in LBD Over Time
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 94 people, planned
- Started
- 22 Apr 2022
- Expected to end
- Feb 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Pimavanserin
- Quetiapine
- Record updated
- 9 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with hallucinations or delusions caused by Parkinson's disease or dementia with Lewy bodies who need to start an antipsychotic medicine. It compares pimavanserin and quetiapine.
- Sex
- All sexes can join.
- Disease stage
- Psychosis (hallucinations and/or delusions) due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB).
- Earlier treatment
- Must need to start an antipsychotic medicine. People currently taking an antipsychotic cannot join.
Main reasons for not taking part
- A medical reason why either medicine cannot be used
- No caregiver available to complete the NPI-Q
- Currently taking an antipsychotic medicine
- The prescribing provider is unwilling to manage either medicine
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients seen in the neurology clinic at UT Health San Antonio
- Diagnosed with psychosis due to PD or DLB
- Requiring initiation of an antipsychotic medication
- Clinical equipoise between quetiapine and pimavanserin must exist
- The prescribing provider must be comfortable prescribing and managing both quetiapine and pimavanserin
Who cannot take part
- Medical contraindication to either medication
- Currently taking an antipsychotic medication
- Prescribing provider unwilling to manage either medication
- Caregiver unavailable to complete NPI-Q
Where in United States
- University Health SystemSan Antonio, United StatesContact: Sarah Horn, MDTaking people
- UT Health Science Center San AntonioSan Antonio, United StatesContact: Carolyn PaizTaking people
About the trial
What the trial wants to find out
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).
The 2 groups in the trial
- quetiapineExisting treatment, for comparison
Elderly patients with dementia-related psychosis will be treated with quetiapine, an atypical antipsychotic indicated for the treeatment of: schizophrenia, bipolar I manic episodes and bipolar depressive episodes.
- pimavanserinExisting treatment, for comparison
Elderly patients with dementia-related psychosis will be treated with pimavanserin, an atypical antipsychotic indicated for treatment of hallucinations and delusions associated with Parkinson's disease.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Pragmatic Randomized Trial Comparing Antipsychotics in Lewy Body Disease
- Plain-language title
- Comparing two antipsychotic medicines for psychosis in Lewy body diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 September 2025